Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. 2005

Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8543, Japan.

Survivin and livin are highly expressed in cancer cells and transformed cells, but show little or no expression in normal differentiated tissues. Although human antibody responses to cancer-associated antigens have been detected, the response to livin has not yet been described in lung cancer patients. We examined prevalence of anti-livin antibodies in such patients with a specific enzyme-linked immunosorbent assay (ELISA) using recombinant protein. Using a cutoff value for positivity determined as the mean absorbance +2S.D. for healthy control samples, 19 of 37 lung cancer patients (51.3%) were positive for anti-livin antibodies. Of 31 samples from the same lung cancer patients, 18 (58.1%) were positive for anti-survivin antibodies. When sera from 31 lung cancer patients were assessed simultaneously by anti-survivin and anti-livin ELISAs. Twenty-one patients (71%) were positive for survivin, livin, or both. Intensity of anti-livin antibody responses did not correlate with intensity of anti-survivin responses. Like anti-survivin antibodies, anti-livin antibodies, thus, can be detected in many lung cancer patients. Testing for both antibodies together may prove useful in detecting lung cancer, but more extensive studies are needed to establish the clinical significance of anti-livin antibodies.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008869 Microtubule-Associated Proteins High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules. Ensconsin,Epithelial MAP, 115 kDa,Epithelial Microtubule-Associate Protein, 115 kDa,MAP4,Microtubule Associated Protein,Microtubule Associated Protein 4,Microtubule Associated Protein 7,Microtubule-Associated Protein,Microtubule-Associated Protein 7,E-MAP-115,MAP1 Microtubule-Associated Protein,MAP2 Microtubule-Associated Protein,MAP3 Microtubule-Associated Protein,Microtubule Associated Proteins,Microtubule-Associated Protein 1,Microtubule-Associated Protein 2,Microtubule-Associated Protein 3,7, Microtubule-Associated Protein,Associated Protein, Microtubule,E MAP 115,Epithelial Microtubule Associate Protein, 115 kDa,MAP1 Microtubule Associated Protein,MAP2 Microtubule Associated Protein,MAP3 Microtubule Associated Protein,Microtubule Associated Protein 1,Microtubule Associated Protein 2,Microtubule Associated Protein 3,Microtubule-Associated Protein, MAP1,Microtubule-Associated Protein, MAP2,Microtubule-Associated Protein, MAP3,Protein 7, Microtubule-Associated,Protein, Microtubule Associated,Protein, Microtubule-Associated
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077022 Survivin An apoptosis inhibitory protein that contains a single baculoviral IAP repeat (BIR) domain. It associates with MICROTUBULES and functions to regulate cell proliferation as a component of the chromosome passage protein complex (CPC), performing essential roles for localization of the complex, chromosome alignment, segregation during MITOSIS and CYTOKINESIS, and assembly of the MITOTIC SPINDLE. It is expressed by fetal kidney and liver cells and highly expressed in ADENOCARCINOMA and high-grade LYMPHOMA. BIRC5 Protein,Baculoviral IAP Repeat-containing Protein 5,Baculoviral IAP Repeat containing Protein 5
D000912 Antibodies, Neoplasm Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS. Neoplasm Antibodies,Tumor Antibodies,Antibodies, Tumor
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody

Related Publications

Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
July 2010, The Journal of veterinary medical science,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
December 2008, Lung cancer (Amsterdam, Netherlands),
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
February 2011, Journal of clinical gastroenterology,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
December 2004, Lung cancer (Amsterdam, Netherlands),
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
October 1994, Ryumachi. [Rheumatism],
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
January 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
February 2007, Autoimmunity,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
August 2006, The Medical journal of Malaysia,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
March 2013, International journal of cancer,
Atsuhito Yagihashi, and Koichi Asanuma, and Daisuke Kobayashi, and Naoki Tsuji, and Yasuharu Shijubo, and Shosaku Abe, and Yoshihiko Hirohashi, and Toshihiko Torigoe, and Noriyuki Sato, and Naoki Watanabe
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!